ABIO Stock Price, ARCA biopharma Inc Quote, Chart

Market Summary

USD3.38+0.09

Market Closed

2.74%

ABIO Alerts

JANUS HENDERSON GROUP PLC reported owning 7.4% of ABIO [2024-04-11]

ABIO Stock Price

View Fullscreen

ABIO RSI Chart

ABIO Valuation

Market Cap

49.0M

Price/Earnings (Trailing)

-8.17

Price/Sales (Trailing)

24.76

EV/EBITDA

-0.79

Price/Free Cashflow

-9.91

ABIO Price/Sales (Trailing)

ABIO Profitability

EBT Margin

-1027.63%

Return on Equity

-17.09%

Return on Assets

-16.35%

Free Cashflow Yield

-10.09%

ABIO Fundamentals

ABIO Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

5.11%

Rev. Growth (Qtr)

-5.59%

ABIO Earnings

Earnings (TTM)

-6.0M

Earnings Growth (Yr)

-49.26%

Earnings Growth (Qtr)

-84.48%

Breaking Down ABIO Revenue

Last 7 days

4%

Last 30 days

12.7%

Last 90 days

104.9%

Trailing 12 Months

60.2%

How does ABIO drawdown profile look like?

ABIO Financial Health

Current Ratio

23.19

ABIO Investor Care

Shares Dilution (1Y)

0.67%

Diluted EPS (TTM)

-0.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0M	0	0	0
2023	1.1M	1.5M	1.8M	2.0M
2022	0	83.0K	302.0K	672.0K
2021	6.0K	7.0K	10.0K	13.0K
2020	158.0K	112.0K	63.0K	28.0K
2019	159.0K	164.0K	174.0K	172.0K
2018	163.0K	167.0K	163.0K	162.0K
2017	193.0K	185.0K	176.0K	167.0K
2016	34.0K	79.0K	128.0K	169.0K
2015	6.0K	6.0K	8.0K	14.0K
2014	6.0K	7.0K	7.0K	7.0K
2013	0	4.0K	6.0K	6.0K
2012	0	3.0K	4.0K	0
2011	572.8K	382.5K	192.3K	2.0K
2010	0	0	0	763.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ARCA biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 16, 2022	funicular funds, lp	acquired	3,550,000	2.5	1,420,000	-
Dec 08, 2022	dekker c. jeffrey	acquired	-	-	40,000	chief financial officer
Dec 08, 2022	keuer thomas a	acquired	-	-	40,000	chief operating officer
Jul 01, 2022	funicular funds, lp	sold	-	-	-2,580,450	-
Jul 01, 2022	funicular funds, lp	acquired	-	-	2,580,450	-
May 25, 2022	funicular fund, lp	bought	150,740	2.3244	64,851	-
May 24, 2022	funicular fund, lp	bought	41,383	2.2851	18,110	-
May 23, 2022	funicular fund, lp	bought	5,280	2.295	2,301	-
May 19, 2022	funicular fund, lp	bought	2.25	2.25	1.00	-
May 18, 2022	funicular fund, lp	bought	30,125	2.3046	13,072	-

Which funds bought or sold ABIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Parallel Advisors, LLC	unchanged	-	14.00	429	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-97.00	-	-	-%
Apr 24, 2024	BML Capital Management, LLC	unchanged	-	42,416	1,244,200	0.82%
Mar 11, 2024	VANGUARD GROUP INC	added	0.68	-134,458	771,117	-%
Feb 20, 2024	Cable Car Capital LLC	new	-	6,800,770	6,800,770	7.06%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-94,365	-	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-22,052	120,933	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	38.71	11.00	73.00	-%
Feb 14, 2024	Newtyn Management, LLC	reduced	-10.23	-145,156	457,844	0.09%

Are Funds Buying or Selling ABIO?

Are funds buying ABIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABIO

No. of Funds

ABIO Alerts

JANUS HENDERSON GROUP PLC reported owning 7.4% of ABIO [2024-04-11]

Unveiling ARCA biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 29, 2024	venrock healthcare capital partners iii, l.p.	5.2%	754,669	SC 13G
Apr 15, 2024	allostery investments lp	7.3%	1,065,016	SC 13G
Apr 11, 2024	janus henderson group plc	7.4%	1,080,107	SC 13G
Apr 09, 2024	avidity partners management lp	6.9%	1e+06	SC 13G
Apr 05, 2024	adage capital management, l.p.	8.28%	1,200,000	SC 13D
Apr 05, 2024	western standard llc	-	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	4.9%	706,930	SC 13G/A
Sep 11, 2023	western standard llc	-	0	SC 13G
Feb 08, 2023	bml investment partners, l.p.	5.95%	858,256	SC 13G/A
Jul 08, 2022	funicular funds, lp	17.91%	2,580,452	SC 13D/A

Recent SEC filings of ARCA biopharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	SC 13G	Major Ownership Report
Apr 25, 2024	10-Q	Quarterly Report
Apr 25, 2024	425	Prospectus Filed
Apr 25, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report
Apr 15, 2024	SC 13G	Major Ownership Report
Apr 11, 2024	SC 13G	Major Ownership Report
Apr 09, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	SC 13D	13D - Major Acquisition
Apr 05, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to ARCA biopharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

ARCA biopharma Inc News

Latest updates

ARCA biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-5.6%	473,000	501,000	513,000	493,000	450,000	374,000	222,000	72,000	4,000	4,000	3,000	2,000	1,000	1,000	2,000	24,000	36,000	50,000	48,000	38,000	38,000
Operating Expenses	56.1%	2,482,000	1,590,000	1,937,000	1,973,000	1,796,000	1,548,000	2,552,000	3,219,000	5,680,000	4,716,000	4,837,000	4,102,000	5,126,000	1,990,000	1,310,000	1,340,000	1,278,000	1,247,000	1,508,000	1,781,000	1,527,000
S&GA Expenses	50.2%	2,317,000	1,543,000	1,615,000	1,719,000	1,406,000	1,487,000	1,528,000	1,734,000	1,739,000	1,278,000	1,260,000	1,226,000	1,922,000	939,000	938,000	975,000	894,000	900,000	1,068,000	1,119,000	902,000
R&D Expenses	251.1%	165,000	47,000	322,000	254,000	390,000	61,000	1,024,000	1,485,000	3,941,000	3,438,000	3,577,000	2,876,000	3,204,000	1,051,000	372,000	365,000	384,000	347,000	440,000	662,000	625,000
EBITDA Margin	1.2%	-10.26	-10.38	-11.10	-13.20	-18.17	-30.24	-67.28	-244	-1,563	-1,664	-1,891	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	3,000	4,000	-	1,000	3,000	3,000	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,000	-	-16,000	-42,000	-27,000	-82,000	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-5,676,000	-4,712,000	-4,834,000	-	-5,125,000	-1,991,000	-1,311,000	-1,320,000	-1,242,000	-1,198,000	-1,463,000	-1,746,000	-1,489,000
EBT Margin	1.2%	-10.28	-10.40	-11.12	-13.22	-18.20	-30.28	-67.37	-245	-1,565	-1,666	-1,894	-	-	-	-	-	-	-	-	-	-
Net Income	-84.5%	-2,009,000	-1,089,000	-1,424,000	-1,480,000	-1,346,000	-1,174,000	-2,333,000	-3,147,000	-5,676,000	-4,712,000	-4,834,000	-4,100,000	-5,125,000	-1,991,000	-1,302,000	-1,320,000	-1,226,000	-1,156,000	-1,436,000	-1,664,000	-1,489,000
Net Income Margin	-11.1%	-3.03	-2.73	-2.96	-4.12	-7.16	-14.77	-47.77	-202	-1,486	-1,877	-2,292	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-44.7%	-1,528,000	-1,056,000	-1,669,000	-694,000	-1,595,000	-1,494,000	-2,498,000	-2,622,000	-4,954,000	-4,884,000	-3,736,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.1%	37.00	38.00	39.00	41.00	42.00	43.00	45.00	48.00	51.00	55.00	60.00	65.00	69.00	50.00	52.00	12.00	7.00	9.00	10.00	10.00	9.00
Current Assets	-2.5%	37.00	38.00	39.00	41.00	42.00	43.00	45.00	48.00	51.00	54.00	60.00	65.00	69.00	50.00	52.00	12.00	7.00	8.00	10.00	10.00	9.00
Cash Equivalents	-4.1%	36.00	37.00	38.00	40.00	41.00	42.00	44.00	46.00	49.00	53.00	58.00	63.00	67.00	49.00	51.00	11.00	7.00	8.00	10.00	10.00	8.00
Net PPE	-30.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	88.0%	2.00	1.00	1.00	2.00	2.00	1.00	2.00	3.00	3.00	4.00	4.00	4.00	3.00	4.00	3.00	2.00	2.00	1.00	-	-	-
Current Liabilities	148.2%	2.00	1.00	1.00	2.00	1.00	1.00	2.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-5.1%	35.00	37.00	38.00	39.00	41.00	42.00	43.00	45.00	48.00	51.00	57.00	61.00	66.00	47.00	50.00	10.00	6.00	8.00	9.00	9.00	7.00
Retained Earnings	-1.1%	-190	-188	-187	-186	-184	-183	-182	-179	-176	-173	-167	-163	-158	-154	-149	-147	-145	-144	-143	-142	-140
Additional Paid-In Capital	0.1%	226	226	226	225	225	225	225	225	225	225	224	224	224	201	199	157	152	152	152	151	148
Shares Outstanding	0%	15.00	15.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	13.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	21.00	-	-	-	29.00	-	-	-	50.00	-	-	-	15.00	-	-	-	11.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-44.7%	-1,528	-1,056	-1,669	-694	-1,595	-1,494	-2,498	-2,622	-4,298	-4,947	-4,870	-3,720	-5,225	-2,995	-2,002	-1,042	-1,686	-1,158	-887	-1,190	-1,566
Share Based Compensation	-19.1%	114	141	154	187	204	120	97.00	172	167	119	104	133	141	18.00	5.00	4.00	16.00	27.00	29.00	45.00	50.00
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-2.00	-7.00	-14.00	-16.00	-6.00	-13.00	-	-3.00	-3.00	-2.00	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-	-	23,093	984	42,056	-	-	-122	568	3,150	2,964

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABIO Income Statement

2024-03-31

STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Costs and expenses:
General and administrative	$ 2,317	$ 1,406
Research and development (related party - $0 and $108 as of March 31, 2024 and 2023, respectively)	165	390
Total costs and expenses	2,482	1,796
Loss from operations	(2,482)	(1,796)
Interest and other income	473	450
Net loss	$ (2,009)	$ (1,346)
Net loss per share:
Basic	$ (0.14)	$ (0.09)
Diluted	$ (0.14)	$ (0.09)
Weighted average shares outstanding:
Basic	14,501,143	14,410,143
Diluted	14,501,143	14,410,143

ABIO Balance Sheet

2024-03-31

BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,903	$ 37,431
Other current assets	767	161
Total current assets	36,670	37,592
Right-of-use asset - operating	17	247
Property and equipment, net	7	10
Other assets	12	12
Total assets	36,706	37,861
Current liabilities:
Accounts payable	529	362
Accrued compensation and employee benefits	84	100
Accrued expenses and other liabilities	968	175
Total current liabilities	1,581	637
Operating lease liability, net of current portion	0	204
Total liabilities	1,581	841
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 100 million shares authorized at March 31, 2024 and December 31, 2023; 14,501,143 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	14	14
Additional paid-in capital	225,861	225,747
Accumulated deficit	(190,750)	(188,741)
Total stockholders’ equity	35,125	37,020	$ 40,531
Total liabilities and stockholders’ equity	$ 36,706	$ 37,861

About ARCA biopharma Inc

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

CEO	Dr. Michael R. Bristow M.D., Ph.D.
WEBSITE	arcabio.com
INDUSTRY	Biotechnology
EMPLOYEES	5

ARCA biopharma Inc Frequently Asked Questions

What is the ticker symbol for ARCA biopharma Inc? What does ABIO stand for in stocks?

ABIO is the stock ticker symbol of ARCA biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ARCA biopharma Inc (ABIO)?

As of Wed May 08 2024, market cap of ARCA biopharma Inc is 49.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABIO stock?

You can check ABIO's fair value in chart for subscribers.

What is the fair value of ABIO stock?

You can check ABIO's fair value in chart for subscribers. The fair value of ARCA biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ARCA biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ARCA biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether ABIO is over valued or under valued. Whether ARCA biopharma Inc is cheap or expensive depends on the assumptions which impact ARCA biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABIO.

What is ARCA biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, ABIO's PE ratio (Price to Earnings) is -8.17 and Price to Sales (PS) ratio is 24.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ARCA biopharma Inc's stock?

In the past 10 years, ARCA biopharma Inc has provided -0.326 (multiply by 100 for percentage) rate of return.